secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001404644-25-000082
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports Q2 net loss $22M; cash $274.5M, FDA agrees on registrational trial design for Rett gene therapy
--------------------------------------------------------------------------------

- Net loss of $22.0M for Q2 2025 vs $18.5M in Q2 2024; R&D expenses $19.4M vs $15.7M.
- Cash, cash equivalents and short-term investments $274.5M as of June 30, 2025; runway into early 2028.
- FDA provided written agreement on key elements of Embolden registrational trial for NGN-401; sample size refined to propose 20 participants.
- Completed dosing in Phase 1/2 NGN-401 trial; last 5 participants dosed in H1 2025; updated clinical data expected H2 2025.
- No evidence of HLH/hyperinflammatory syndrome in any NGN-401 participant at 1E15 vg dose level as of press date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000082/0001404644-25-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000082/ngne-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer